How do antibodies access neurons to fight infection?

Influenza virus cells, high-lighted through a florescent microscope, are identified during tests at the World Health Organization (WHO) National Influenza Center in Bangkok on October 21, 2005. Thailand awaited test results on another suspected bird flu case on Friday after a resurgence of the killer virus in Asia, although Indonesian fears the H5N1 strain was mutating eased as a father and son proved negative.

Yale scientists have uncovered how antibodies are able to control viruses from the nervous system. Image: REUTERS/Adrees Latif

Ziba Kashef
Senior Writer, Editor and Communications Consultant, Yale University Office of Public Affairs and Communications
Share:
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale

Yale scientists have solved a puzzle of the immune system: how antibodies enter the nervous system to control viral infections. Their finding may have implications for the prevention and treatment of a range of conditions, including herpes and Guillain-Barre syndrome, which has been linked to the Zika virus.

Many viruses — such as West Nile, Zika, and the herpes simplex virus — enter the nervous system, where they were thought to be beyond the reach of antibodies. Yale immunobiologists Akiko Iwasaki and Norifumi Iijima used mice models to investigate how antibodies could gain access to nerve tissue in order to control infection.

In mice infected with herpes, they observed a previously under-recognized role of CD4 T cells, a type of white blood cell that guards against infection by sending signals to activate the immune system. In response to herpes infection, CD4 T cells entered the nerve tissue, secreted signaling proteins, and allowed antibody access to infected sites. Combined, CD4 T cells and antibodies limited viral spread.

“This is a very elegant design of the immune system to allow antibodies to go to the sites of infection,” said Iwasaki. “The CD4 T cells will only go to the site where there is a virus. It’s a targeted delivery system for antibodies.”

The finding has multiple implications, said the researchers. Without CD4 T cells, antibody-based therapies that are being developed for conditions like herpes may not be sufficient to control infection, Iwasaki noted. Conversely, for antibody-mediated autoimmune diseases such as Guillain-Barre, “it may be beneficial to block CD4 from entering the neuronal tissues,” she said.

The study was funded by the National Institutes of Health, and the Howard Hughes Medical Institute and was published May 18 in Nature.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum